Boone Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Boone Capital Management reported a $428M portfolio of 16 positions to the SEC as of the end of Q2 2026. Its largest positions are TFX, MIRM, CI. During the quarter it opened Vestis and Pennant Group and exited Medtronic and Astrazeneca.
Sections with a free account
What changed this quarter
20 positions with a change (7 new, 8 added to, 1 trimmed, 4 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Medtronic−8.1 ppof portfolioSold out10.6% → —
- Vestis+6.5 ppof portfolioNew— → 6.5%
- Astrazeneca−5.1 ppof portfolioSold out6.7% → —
- Pennant Group+4.5 ppof portfolioNew— → 4.5%
- Avanos Medical−3.9 ppof portfolioSold out5.1% → —
- Monte Rosa Therapeutics+3.5 ppof portfolioNew— → 3.5%
- Tango Therapeutics+3.3 ppof portfolioNew— → 3.3%
- Teleflex+39%more sharesIncreased10.2% → 11.5%
- Kymera Therapeutics+3.0 ppof portfolioNew— → 3.0%
- Cullinan Therapeutics+3.0 ppof portfolioNew— → 3.0%
- BridgeBio Pharma+48%more sharesIncreased5.2% → 5.9%
- Cigna Group+16%more sharesIncreased11.2% → 10.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- TeleflexTFX11.5%
- Mirum PharmaceuticalsMIRM11.4%
- Cigna GroupCI10.3%
- Ionis PharmaceuticalsIONS9.6%
- UnitedHealth GroupUNH8.6%
- BioMarin PharmaceuticalBMRN7.8%
- Guardian Pharmacy ServicesGRDN7.0%
- VestisVSTS6.5%
- BridgeBio PharmaBBIO5.9%
- Pennant GroupPNTG4.5%
- Monte Rosa TherapeuticsGLUE3.5%
- Kodiak SciencesKOD3.4%
- Tango TherapeuticsTNGX3.3%
- Kymera TherapeuticsKYMR3.0%
- Cullinan TherapeuticsCGEM3.0%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 87%
- ● Consumer Staples 7%
- ● Industrials 6%
How its portfolio changed (8 quarters)
Q2 2026: 16
Q2 2026: 83%
Q2 2026: 26.2%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 30, 2026 (high confidence).
The data, as reported: BOONE CAPITAL MANAGEMENT LLC (CRD 316230): 7.B private funds: 1 hedge (gross assets $963M); 5.D assets by client type: pooled vehicles 100% (of $963M)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Oldfield Partners LLPInvestment firm · $428M
- CAT Rock Capital ManagementInvestment firm · $431M
- Miller Value PartnersInvestment firm · $423M
- Grandeur Peak Global AdvisorsInvestment firm · $432M
- Seafarer Capital PartnersInvestment firm · $434M
- Divisar Capital ManagementInvestment firm · $434M